Ardelyx, Inc. (ARDX)
3.27
+0.08
(+2.51%)
USD |
NASDAQ |
Oct 15, 16:00
3.30
+0.03
(+0.92%)
After-Hours: 20:00
Ardelyx Research and Development Expense (Quarterly) : 25.50M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.50M |
| March 31, 2026 | 19.27M |
| December 31, 2025 | 21.94M |
| September 30, 2025 | 17.16M |
| June 30, 2025 | 15.04M |
| March 31, 2025 | 14.34M |
| December 31, 2024 | 13.15M |
| September 30, 2024 | 14.77M |
| June 30, 2024 | 12.19M |
| March 31, 2024 | 10.14M |
| December 31, 2023 | 9.162M |
| September 30, 2023 | 8.346M |
| June 30, 2023 | 7.64M |
| March 31, 2023 | 9.096M |
| December 31, 2022 | 9.033M |
| September 30, 2022 | 6.839M |
| June 30, 2022 | 9.566M |
| March 31, 2022 | 8.619M |
| December 31, 2021 | 20.77M |
| September 30, 2021 | 23.24M |
| June 30, 2021 | 25.66M |
| March 31, 2021 | 20.03M |
| December 31, 2020 | 17.68M |
| September 30, 2020 | 11.80M |
| June 30, 2020 | 18.40M |
| Date | Value |
|---|---|
| March 31, 2020 | 15.35M |
| December 31, 2019 | 11.89M |
| September 30, 2019 | 17.58M |
| June 30, 2019 | 19.48M |
| March 31, 2019 | 20.38M |
| December 31, 2018 | 22.04M |
| September 30, 2018 | 17.94M |
| June 30, 2018 | 16.05M |
| March 31, 2018 | 13.35M |
| December 31, 2017 | 17.16M |
| September 30, 2017 | 14.76M |
| June 30, 2017 | 20.57M |
| March 31, 2017 | 22.39M |
| December 31, 2016 | 26.21M |
| September 30, 2016 | 24.86M |
| June 30, 2016 | 23.84M |
| March 31, 2016 | 19.25M |
| December 31, 2015 | 12.78M |
| September 30, 2015 | 14.70M |
| June 30, 2015 | 6.198M |
| March 31, 2015 | 6.198M |
| December 31, 2014 | 7.286M |
| September 30, 2014 | 5.62M |
| June 30, 2014 | 5.128M |
| March 31, 2014 | 7.564M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Capricor Therapeutics, Inc. | 28.57M |
| REGENXBIO, Inc. | 52.33M |
| Compass Therapeutics, Inc. | 19.56M |
| ARS Pharmaceuticals, Inc. | 4.698M |
| Sionna Therapeutics, Inc. | 21.86M |